INTRODUCTION
Anthracyclines (AC) are highly effective chemotherapeutic agents, whose full clinical potential is limited by cardiac toxicity (ACT) [1] [2] [3] [4] . ACT is progressive, may become manifested many years after the completion of treatment and occurs at variable threshold doses [5] [6] [7] [8] . The evolution of AC-induced subclinical cardiac dysfunction is not clearly understood and other than vigilant monitoring, there are no explicit guidelines for its management [6, [9] [10] [11] . Therefore, each AC recipient requires monitoring for cardiotoxicity for a long period of time, the duration of which is not known.
Monitoring for ACT is most simply accomplished by echocardiographic measures, including fractional shortening (FS) and ejection fraction (EF) [12] . However, these measures are dependent on ventricular loading conditions and lack sensitivity for detecting ACT [13, 14] . FS alone is reduced in 28% of AC-treated patients, whereas 57% have an abnormal left ventricular afterload, as measured by end systolic wall stress (ESWS) or contractility measured by the stress velocity index (SVI) [3] . These more sophisticated parameters are technically difficult to obtain in children. An objective, easily obtained biomarker of ventricular function would greatly add to the clinical care of AC-treated patients.
Plasma B-type natriuretic peptide (BNP) is a cardiac hormone secreted from the ventricles, in response to ventricular volume and pressure overload [15] . Levels increase in proportion to the severity of congestive heart failure (CHF) in adults and children [16] [17] [18] . In the pediatric age group, values of BNP of 7 AE 5.9 and 10.1 AE 8.6 pgÁml À1 have been reported in healthy boys and girls, respectively [19] . Comparable BNP levels are noted in neonates after closure of patent ductus arteriosus and children with cardiomyopathy, without clinical signs of heart failure [20, 21] . The role of BNP in screening for late onset ACT remains to be elucidated. One previous study found plasma BNP to be significantly elevated in patients with a reduction of FS or EF [22] .
The rationale for our study was that plasma BNP may be elevated in AC-treated patients with late cardiac dysfunction. Our primary objective was to evaluate plasma BNP as a screening test for detecting late onset AC-induced cardiac dysfunction, in comparison to detailed sensitive indices, not ordinarily available from a clinical echo.
Since the mid 1990s, cumulative AC doses have been empirically limited to below 550 mgÁm À2 due to the high incidence of clinically important cardiotoxicity observed above this dose [23] . More recently, a further dose reduction to below 250 mgÁm À2 has been suggested to reduce the incidence of ACT [9] . Limited information is available about the impact of progressive AC dose curtailment on the incidence of late cardiac dysfunction. Our secondary aim, therefore, was to define the prevalence of cardiac dysfunction using load-independent echocardiographic measures in a cohort of patients treated with low cumulative AC doses.
MATERIALS AND METHODS
This prospective non-interventional study was conducted at Children's Hospital of Michigan, after approval by the Human Investigation Committee. Patients were enrolled between October 2003 and June 2004 after obtaining written informed consent from parents or guardians.
Selection Criteria
Patients who had completed AC chemotherapy at least 1 year prior to enrollment were included. Patients with congenital heart Background. Anthracyclines (AC) are useful antineoplastic agents, whose utility is limited by progressive cardiotoxicity. Our purpose was to evaluate plasma B-type natriuretic peptide (BNP), as a screening test for detecting late cardiac dysfunction in AC-treated children and to determine the prevalence of late cardiac dysfunction at low cumulative AC doses. Materials and Methods. This was a prospective study in which patients who had completed AC therapy at least 1 year earlier, underwent a detailed echocardiogram and a simultaneous BNP level. Cardiac dysfunction was defined as any one of the following: shortening fraction (FS) <29%, rate corrected velocity of circumferential fiber shortening (VCFc) <0.9 cÁsec
À1
, end systolic wall stress (ESWS) >60 gÁcm À2 , abnormal VCFc: ESWS ratio or decreased mitral inflow velocity (E/A) ratios, compared to age-specific norms. Results. The cohort (n ¼ 63) included 37 males with a median age of 13.1 years (range, 6.5-26.5 years). Cardiac dysfunction was found in 26 (41%) patients and in 40% of patients who received cumulative doses <150 mgÁm À2 . ESWS was the most common abnormality. Mean BNP levels in the subset with abnormal function were significantly higher than the normal group (23.4 AE 25.3 vs. 14.2 AE 8.9 pgÁml
, P ¼ 0.02). Conclusions. Plasma BNP was significantly elevated in AC-treated patients with late cardiac dysfunction, although there was considerable overlap of levels between groups with and without cardiac dysfunction. BNP may need further evaluation as a serial index of cardiac function in this population. Cardiac dysfunction was observed in a significantdisease, cardiomyopathy prior to initiation of chemotherapy, renal failure (serum creatinine more than twice the age-specific norms), patients who received mediastinal radiation, were pregnant or critically ill, were excluded. Each patient underwent an echocardiogram and simultaneous blood draw for BNP assay for research purposes.
Clinical Data
Clinical data obtained for each subject included demographics, clinical diagnosis, the cumulative dose of AC received, time elapsed since the completion of AC therapy, and cardiac symptoms.
Echocardiography
Echocardiograms were performed using a Phillips Sonos 5500 ultrasound machine. Each patient underwent M mode, 2D and Doppler echocardiogram with simultaneous recording of carotid pulse tracing, electrocardiogram, phonocardiogram, and blood pressure. Echo parameters were selected to measure (a) left ventricular systolic function (shortening fraction FS, ejection fraction EF and rate corrected mean velocity of circumferential fiber shortening VCFc), (b) afterload (end systolic wall stress ESWS), (c) contractility (Stress velocity index SVI), and (d) left ventricular diastolic function (peak E and A velocities and their ratio). FS and EF were calculated as described [24, 25] . Shortening fraction below 29% and EF less than 64% were considered abnormal [12, 25] . VCFc was obtained by the method described by Colan et al. [3, 26] and considered abnormal below 0.90 cÁsec À1 . ESWS was calculated by the method described by Grossman et al. and considered abnormal above 60 gÁcm À2 [3, 27] . The SVI or the relationship between VCFc and ESWS were measured by the method described by Colan et al. [26] . A VCFc value two standard deviations below normal in relation to ESWS was considered to represent abnormal contractility [26, 28] . E/A ratio was obtained by pulse Doppler at the mitral valve inflow and compared to established normal values [29] . All echocardiograms were read by a single cardiologist (MP) who was blinded to patient data and results of the BNP assay.
Abnormal cardiac function was defined by any one of the following criteria: FS <29%; VCFc <0.90 cÁsec
À1
; ESWS >60 gÁcm
À2
; abnormal VCFc: ESWS ratio; or decreased E/A ratio, based on age-specific normal values. EF was not included in our preset criteria of cardiac dysfunction due to inherent fallacies in its echocardiographic measurement in the pediatric age group [25] .
Plasma BNP Assay
Blood samples (3 ml) were collected in K-EDTA tubes within 3 hours of the echocardiogram and were centrifuged immediately at 3,500 rpm for 10 min. Platelet-free plasma was stored at À208C. BNP assay was performed using the Triage BNP kit (Biosite Diagnostic, San Diego, California).
Statistical Analysis
Statistical analyses were performed using SPSS (version 12) software. Sample size was predetermined using a two-tailed test with a significance (alpha) set at 0.05 to achieve a power of 81%, based on the assumption that the BNP would be higher in patients with abnormal heart function on echocardiogram by 20 pgÁdl À1 (corresponding to means AE SD of 9 AE 14.8 and 29 AE 31.2, respectively, based on a prior study) [22] . The number of patients required to achieve a power of 80% was 23 in each group. Since 50-60% of pediatric patients who receive AC have abnormal contractility and/or afterload, we enrolled 63 patients with an expectation of two nearly equal subsets-those with and without cardiac dysfunction [3] . Data were expressed as mean AE SD for continuous variables and as a number (percentage) for categorical variables. The two groups were compared for continuous variables using the Student t-test for independent samples [30] . Box and whisker plots of BNP levels were used to show the distribution in the subgroups based on cardiac function. Statistical significance was set as P < 0.05. All hypotheses were two tailed.
RESULTS

Subject Characteristics
Eighty patients were identified from the echo database in the cardiology clinic. Two could not be traced and 15 patients refused consent. Sixty-three patients were enrolled in the study including 37 (59%) males and 26 (41%) females. The median age at enrollment was 13.1 years (range, 6.5-26.5) and the median interval since completion of AC treatment was 3. ) and 6 patients (9.5%) had an abnormal stress velocity index. All three patients with clinical CHF had low FS; two had four abnormal parameters (FS, ESWS, VCFc, and SVI). Diastolic function (peak E/A velocities and their ratio) was normal in all patients, with the E/A ratios ranging from 1.33 to 3.05, with a mean (SD) of 2.06 AE 0.43 (median 2.03). Baseline characteristics of the groups with normal and abnormal cardiac function are shown (Table I ). The two groups were similar in the mean cumulative dose of AC received (204.7 AE 100.6 mgÁm , n¼ 26 vs. 14.2 AE 8.9 pgÁdl À1 , n¼ 37, P ¼ 0.02; Fig. 1 ). Plasma BNP levels were higher when FS was low (32.4 AE 34.9 (n ¼ 9) vs. 15.6 AE 12.4 (n ¼ 54), P < 0.008). When all four systolic parameters were abnormal, plasma BNP was significantly higher than when one to three parameters were abnormal (69.2 AE 67.1 (n ¼ 2) vs. 19.6 AE 17.3 (n ¼ 24), P < 0.005). Plasma BNP levels in the five subjects on cardiac medications were significantly higher than the rest of the cohort (49.8 AE 40.2 vs. 15.2 AE 11.9 pgÁml À1 , P < 0.001). When the five patients on medications were excluded, BNP levels remained significantly higher when cardiac function was abnormal than when function was normal (19.4 AE 17.6 vs. 14.1 AE 8.9, P ¼ 0.02). Table III depicts the mean plasma BNP levels in the subgroups with normal and abnormal function for each echocardiographic parameter. Plasma BNP was significantly higher in patients with abnormal FS, VCFc, and SVI, but not ESWS.
DISCUSSION
Among AC-treated patients, 41% had an abnormality of cardiac function at a mean follow-up interval of 5.2 years, the majority of whom were asymptomatic. Nine (14%) patients had abnormal FS and EF, the commonly used clinical parameters. The most sensitive echo parameter for diagnosis of subclinical ACT was ESWS, representing 80% of cardiac abnormalities, while contractility by SVI was abnormal in only 24% of patients. Patients receiving doses as low as 90 mgÁm À2 had cardiac dysfunction. Plasma BNP was significantly higher in patients with cardiac dysfunction and when multiple echo parameters were abnormal. Plasma BNP was significantly elevated in the presence of abnormal contractility, although the elevation of BNP with increased ESWS did not reach statistical significance. These findings assume importance, given the growing numbers of AC treated patients and that AC use is mainly limited by cardiotoxicity [5] [6] [7] 31] .
Our finding of the association of an elevated BNP with late ACinduced cardiac dysfunction is similar to studies in adults, where a significant increase in plasma BNP has been noted in AC-treated patients with clinical or subclinical heart failure [32] [33] [34] . Previous data in children are limited. While one previous study reported elevation of plasma BNP (29 AE 31.2 vs. 9 AE 14.8 pgÁml À1 ) in patients with left ventricular dysfunction, compared to patients with normal function, another reported higher BNP levels in the ACtreated group as a whole, compared to untreated controls (10.5 AE 10.2 vs. 4.09 AE 2.2 pgÁml À1 ) [22, 35] . Both studies enrolled patients soon after completion of AC therapy when LV dysfunction could represent acute toxicity, which is not predictive of late ACT. Neither study excluded patients who had received chest radiation, which can worsen ACT. Moreover, VCFc, ESWS, and SVI were not utilized.
To our knowledge, ours is the largest study to evaluate plasma BNP for the detection of late ACT using sensitive echocardiographic indices. We believe our finding of a mild but significant elevation in plasma BNP with cardiac dysfunction is of clinical interest. Although largely asymptomatic, an increase in plasma BNP may Pediatr Blood Cancer DOI 10.1002/pbc be a biochemical surrogate for subtle but potentially progressive cardiac dysfunction. Indeed, the value of plasma BNP may lie in serial monitoring, where a change in plasma BNP may predict a decline in cardiac function for an individual patient. Further studies are needed to evaluate plasma BNP in this manner. We are currently conducting such a study. A limitation of our study is that although plasma BNP was significantly higher from a statistical standpoint in patients with cardiac dysfunction, there was wide variation in the levels, precluding determination of a cut-off level with high sensitivity and specificity to discriminate between patients with normal cardiac function from those without. The overlap of BNP levels makes it unwise to use BNP as a sole screening method for ACT. BNP could not differentiate abnormal from normal ESWS in our study (mean BNP 23.5 abnormal vs. 15.4 normal ESWS). We suspect that our small sample size was not powered to detect differences in BNP in the subgroups for each individual echocardiographic parameter, which larger studies may uncover.
We also report the prevalence and characteristics of late cardiac dysfunction at curtailed AC doses, using sensitive echocardiographic parameters. Our observed prevalence of late cardiac abnormalities is similar to recent reports in which the mean cumulative AC doses were approximately 300 mgÁm À2 [9, [36] [37] [38] [39] .
Our finding that even in the children who received cumulative doses below 150 mgÁm À2 , 40% had late cardiac dysfunction is novel and disturbing. We did not detect diastolic dysfunction in any of our patients, conflicting with some previous studies but consistent with others [40] [41] [42] . The established correlation between cumulative AC dose and cardiac dysfunction was not noted in our dataset, probably due to the small sample size.
Plasma BNP was significantly elevated in patients with late ACinduced cardiac dysfunction, although there was considerable overlap of levels in patients with normal and abnormal function. Serial measures of plasma BNP merit further evaluation for monitoring of AC-related cardiotoxicity. Even when treated with low cumulative AC doses, about 40% of AC-treated children had abnormal ventricular function. 
